| Not Yet Recruiting | European LUpuS Inception-Cohort Developing initiATivE NCT07209540 | University of Aarhus | — |
| Recruiting | To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus NCT07447986 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 2 |
| Recruiting | Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatme NCT07490041 | The Children's Hospital of Zhejiang University School of Medicine | EARLY_Phase 1 |
| Recruiting | Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic D NCT07087912 | University of Sao Paulo General Hospital | Phase 4 |
| Recruiting | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease NCT07332481 | EMD Serono Research & Development Institute, Inc. | Phase 3 |
| Not Yet Recruiting | YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases NCT07439029 | Children's Hospital of Fudan University | Phase 1 |
| Withdrawn | A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases NCT06913608 | Calibr, a division of Scripps Research | Phase 1 |
| Recruiting | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (S NCT06875960 | Bristol-Myers Squibb | Phase 4 |
| Not Yet Recruiting | It is an Observational Study That Compare Prognosis of Typical and Atypical Systemic Lupus Erythematosus Prese NCT07350772 | Sohag University | — |
| Recruiting | Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus NCT07425730 | Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopath NCT07331272 | Nanjing Legend Biotech Co. | Phase 1 |
| Recruiting | A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases NCT07413341 | Therorna | Phase 1 |
| Recruiting | A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell NCT07339332 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Not Yet Recruiting | BCMA-CD19 cCAR T for the Treatment of Refractory Lupus NCT07328581 | iCell Gene Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | miR-101-3p and Autotaxin in SLE Patients NCT07252141 | Eman Mohamed Shawky | — |
| Not Yet Recruiting | The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subj NCT07306585 | HC Biopharma Inc. | Phase 1 |
| Recruiting | A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus NCT07444307 | Hangzhou Qihan Biotech Co., Ltd. | Phase 1 |
| Recruiting | The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephri NCT07340463 | Nanjing University School of Medicine | Phase 2 |
| Recruiting | Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases NCT07236801 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus NCT06900764 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Recruiting | A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids a NCT07175285 | Bristol-Myers Squibb | — |
| Recruiting | The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE NCT07185269 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Clinical Study of Cizutamig in Systemic Lupus Erythematosus NCT07215663 | Candid Therapeutics | Phase 1 |
| Recruiting | An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmun NCT07174843 | Shanghai Cell Therapy Group Co.,Ltd | EARLY_Phase 1 |
| Recruiting | Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus NCT07010835 | Excyte Biopharma Ltd | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases NCT07123519 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases NCT07104721 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE NCT07031713 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Recruiting | Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells NCT07041801 | Shenzhen Beike Bio-Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE NCT06892145 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Not Yet Recruiting | An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus NCT06945068 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Recruiting | A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases NCT06980597 | Beijing GoBroad Hospital | Phase 1 |
| Recruiting | A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus NCT06839976 | Children's Hospital of Philadelphia | Phase 1 / Phase 2 |
| Recruiting | Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE) NCT06902844 | Tongji Hospital | N/A |
| Recruiting | Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus NCT06946485 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | EARLY_Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Disease NCT06647069 | Sanofi | Phase 1 |
| Recruiting | A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity o NCT06799520 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 |
| Completed | Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE NCT06720584 | Duke University | N/A |
| Recruiting | CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or NCT06822881 | Beijing GoBroad Hospital | Phase 1 |
| Completed | AZAHAR Study To Describe Anifrolumab in a Real-World Setting NCT06626945 | AstraZeneca | — |
| Enrolling By Invitation | Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases NCT06888973 | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | Phase 1 / Phase 2 |
| Recruiting | A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus NCT06653556 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Recruiting | UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients NCT06737380 | LiveKidney.Bio | Phase 1 |
| Recruiting | Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus NCT06789107 | Mao Jianhua | Phase 1 |
| Enrolling By Invitation | A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease NCT06375993 | Adicet Therapeutics | Phase 1 |
| Recruiting | Safety Study of CC312 in Autoimmune Disease Patients NCT06888960 | CytoCares Inc | EARLY_Phase 1 |
| Completed | Hematological Manifestations in Systemic Lupus Erythematosus Patients NCT06936007 | Patan Academy of Health Sciences | — |
| Recruiting | INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use NCT06314282 | AstraZeneca | — |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus NCT06585514 | Beijing GoBroad Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Immune Cell Subsets in SLE Patients Treated with Telitacicept NCT06677801 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
| Recruiting | JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) NCT06675422 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 / Phase 2 |
| Recruiting | An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). NCT06335979 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants NCT06625671 | DualityBio Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676 | Polina Stepensky | Phase 1 |
| Completed | Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in SLE Patients NCT07083622 | Universitas Sriwijaya | N/A |
| Completed | Efficacy of Vitamin C Supplementation on Serum TNF-α Levels and Disease Activity in SLE Patients NCT07071233 | Universitas Sriwijaya | N/A |
| Completed | Efficacy of Vitamin C Supplementation on Serum IL-6 Levels and Disease Activity in Systemic Lupus Erythematosu NCT07071220 | Universitas Sriwijaya | N/A |
| Terminated | IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy NCT06462144 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | EARLY_Phase 1 |
| Not Yet Recruiting | The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases NCT06420154 | First Affiliated Hospital of Wenzhou Medical University | EARLY_Phase 1 |
| Active Not Recruiting | Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regul NCT06659068 | Universitas Sriwijaya | N/A |
| Recruiting | Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease NCT06373081 | Shanghai Changzheng Hospital | N/A |
| Recruiting | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease NCT06308978 | Fate Therapeutics | Phase 1 |
| Recruiting | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy NCT06249438 | RenJi Hospital | Phase 1 |
| Recruiting | Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Im NCT06032923 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Descartes-08 for Patients With Systemic Lupus Erythematosus NCT06038474 | Cartesian Therapeutics | Phase 2 |
| Active Not Recruiting | SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus NCT06144710 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 |
| Recruiting | An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus NCT06010472 | Changhai Hospital | EARLY_Phase 1 |
| Recruiting | Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus NCT05988216 | Bioray Laboratories | N/A |
| Recruiting | Lupus Landmark Study: A Prospective Registry and Biorepository NCT05934149 | Lupus Research Alliance | — |
| Enrolling By Invitation | Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases NCT05859997 | Bioray Laboratories | N/A |
| Recruiting | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus NCT05688696 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |
| Active Not Recruiting | 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2 NCT05747651 | University Hospital, Brest | — |
| Unknown | Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythe NCT05724940 | Sohag University | — |
| Recruiting | Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophospham NCT05567198 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | — |
| Completed | Gradual Withdrawal of Low-dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus. NCT06234852 | Phramongkutklao College of Medicine and Hospital | N/A |
| Active Not Recruiting | 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol NCT05458622 | University Hospital, Brest | Phase 3 |
| Active Not Recruiting | A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Ery NCT05411016 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Enrolling By Invitation | An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether Th NCT05352919 | Biogen | Phase 3 |
| Terminated | A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient Wit NCT05140824 | TJ Biopharma Co., Ltd. | Phase 1 |
| Recruiting | Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus NCT04702256 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Terminated | COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders NCT05000216 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE) NCT03975361 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE NCT04726553 | Oklahoma Medical Research Foundation | EARLY_Phase 1 |
| Recruiting | Research Accelerated by You Lupus Registry NCT06927219 | Lupus Foundation of America | — |
| Completed | CCCR Lupus Patient Navigator Program NCT04461158 | Medical University of South Carolina | N/A |
| Completed | A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combinatio NCT04451772 | AbbVie | Phase 2 |
| Completed | Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) NCT04058028 | Amgen | Phase 2 |
| Completed | A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination NCT03978520 | AbbVie | Phase 2 |
| Completed | Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients NCT03656562 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Omega-3 Replacement With Krill Oil in Disease Management of SLE NCT03626311 | Aker BioMarine Human Ingredients AS | N/A |
| Completed | EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study NCT07281105 | Evergreen Therapeutics, Inc. | Phase 2 |
| Terminated | CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid NCT03492255 | University of Sao Paulo General Hospital | N/A |
| Completed | Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases NCT03122431 | University of Sao Paulo General Hospital | Phase 4 |
| Completed | Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE) NCT02782039 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Detection of Annexin A2 in Systemic Lupus Erythematosus NCT03031925 | Centre Hospitalier Universitaire, Amiens | N/A |
| Unknown | A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) NCT03030976 | Shanghai GeneChem Co., Ltd. | Phase 1 |
| Terminated | LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse NCT02811094 | Assistance Publique Hopitaux De Marseille | N/A |
| Withdrawn | Acthar SLE (Systemic Lupus Erythematosus) NCT02779153 | NYU Langone Health | Phase 4 |
| Completed | A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus NCT02804763 | UCB Biopharma S.P.R.L. | Phase 2 |
| Completed | GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus NCT01992666 | Hospices Civils de Lyon | N/A |
| Completed | Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythemat NCT02006784 | Vanderbilt University | — |
| Completed | Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Acti NCT01753401 | Mallinckrodt | Phase 4 |
| Unknown | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases NCT01151644 | University of Sao Paulo | Phase 4 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants NCT05984251 | Amgen | Phase 1 |
| Completed | Auto-immunity in Lupus Patients After Influenza Vaccine NCT01072734 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE) NCT00960362 | Argos Therapeutics | Phase 1 |
| Completed | Prospective Study of Rapamycin for the Treatment of SLE NCT00779194 | State University of New York - Upstate Medical University | Phase 2 |
| Completed | Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus NCT00582881 | University of Miami | — |
| Unknown | Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption NCT00608127 | Verto LTD | N/A |